Home/Pipeline/Jyseleca (filgotinib)

Jyseleca (filgotinib)

Rheumatoid Arthritis

MarketedActive (Commercial)

Key Facts

Indication

Rheumatoid Arthritis

Phase

Marketed

Status

Active (Commercial)

Company

Galapagos, Galapagos

About Galapagos

Galapagos is a commercial-stage biotech transitioning from a platform-centric discovery model to a lean, externally-focused business development engine. Its legacy is anchored by the successful JAK1 inhibitor filgotinib (Jyseleca), developed with Gilead, which provides European revenue and royalties. The company's current strategy, under new leadership, involves winding down internal cell therapy to redeploy capital towards acquiring late-stage clinical assets in high-value therapeutic areas like oncology and immunology, as exemplified by its new T cell engager collaboration with Gilead.

View full company profile

About Galapagos

View full company profile

Therapeutic Areas

Immunology & Inflammation Oncology

Other Rheumatoid Arthritis Drugs

Drug	Company	Phase	Status
Early Detection Test for Rheumatoid Arthritis	Age Labs	Development	Active
Piclidenoson (CF101)	Can Fite Biopharma	Phase II/III	Previously Active
ERNA-201	Eterna Therapeutics	Preclinical	Active Discovery/Research
Tc99m Tilmanocept	Navidea Biopharmaceuticals	Phase 2/3	Jeopardized (Bankruptcy)
Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)	LFB	Pre-clinical	Development (Partnership)
EYD-001 (Takinib analog)	EydisBio	Preclinical	In vivo efficacy and pilot safety in progress
LFD-200	Lifordi Immunotherapeutics	Phase 1	Active
MEV-N01	Mesenbio	Pre-clinical	Active
CIT-013	Citryll	Phase 2a	Active
Restem-L	Restem	Phase 2	Active
ASIT Platform	Ahead Therapeutics	Pre-clinical	Active
AX-158	Artax Biopharma	Phase 2	Active